Skip to content
value.today
Agenus Inc. logo

Agenus Inc.

AGEN
$290 Mmarket cap on Oct 22, 2026-2.2% since Jan 2024
1M
-26.4%
Compare
World rank
#14,929
Revenue
$114 M
For year ending December-2025
Net income
$-3 M
-2.7% margin
SEC filing
Employees
441
As on 2021
value.today research

Agenus Inc. in brief

Agenus Inc. is a listed company in the Biotechnology industry, based in Lexington, Massachusetts, USA. It was founded in 1994. Its market value was $290 M on 22 October 2026, which makes it the 14,929th largest listed company in the world and the 2,909th largest in the USA on this site. In the year to December 2025 it had sales of $114 M and a net loss of $3 M. It employs about 441 people and Garo H. Armen is its chief executive. Its largest product and service lines by sales in 2025 were Pre-Commercial Product Revenue (4%), Service Revenue (under 1%) and Research and Development (under 1%). By market, the largest shares of its 2025 sales came from USA (99%). Its shares trade under the symbol AGEN (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

About Agenus Inc.

Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or cure cancer. The company is developing checkpoint modulators (CPMs), patient-specific anti-cancer vaccines, and adjuvants designed for use with various vaccines. CPM development is a particularly fast-moving field, since early products have produced unprecedented clinical benefits for patients.

From Wikipedia: read the full article · text available under CC BY-SA 4.0

Agenus Inc. timeline

6 events, 1994–2023
  1. 1994
  2. 🏁
    · approximate
    Founded by Garo H. Armen
  3. 1999
  4. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  5. 2000
  6. 🔔
    · approximate
    Initial public offering on Nasdaq as AGEN
  7. 2011
  8. ✎
    Renamed Agenus Inc
    Formerly Antigenics Inc /De/.
  9. 2018
  10. •
    Legal Entity Identifier issued
    LEI 529900NDQQGU5H4UJK81 registered.
  11. 2023
  12. 💰
    Record revenue of $156 million
    FY2023, the highest of the 7 years on record.

Events of Agenus Inc. from Wikidata, SEC EDGAR, the GLEIF LEI register and the company's financial years. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$207 M$415 M$622 M$829 M2020202120222023202420252026

World rank over time

▼ down 4,337 places since 2020
2020-01-01: #10631#10,63120202021-01-01: #10259#10,25920212022-01-07: #10874#10,87420222022-12-25: #10007#10,00720222023-07-30: #12321#12,32120232024-01-05: #15848#15,84820242026-03-08: #9976#9,97620262026-08-01: #13845#13,84520262026-09-23: #13696#13,69620262026-10-22: #14968#14,9682026

Rank in USA: #2,422 (Jan 2020) · #2,601 (Jan 2021) · #2,797 (Jan 2022) · #2,260 (Dec 2022) · #2,630 (Jul 2023) · #2,940 (Jan 2024) · #1,938 (Mar 2026) · #2,798 (Aug 2026) · #2,672 (Sep 2026) · #2,913 (Oct 2026)

Key ratios

market cap and latest results · TTM = trailing 12 months
P/E ratio (TTM)
9.4×
Price / sales (TTM)
2.2×
Price / book
—
Free cash flow yield
-26.7%
Net margin (TTM)
23.0%
Operating margin
-17.7%
Return on equity
—
Liabilities / assets
222.5%
Net debt
$42M
Revenue growth
+10.4%
R&D / revenue
69.5%
Revenue per employee
$259 K
Profit per employee
$-7 K

Financial history

USD · fiscal years · source: SEC filings
RevenueNet income
Fiscal year ending Dec 2018: revenue $37M, net income $-162M$37MFY18Fiscal year ending Dec 2019: revenue $150M, net income $-112M$150MFY19Fiscal year ending Dec 2020: revenue $88M, net income $-183M$88MFY20Fiscal year ending Dec 2021: revenue —, net income $-29M—FY21Fiscal year ending Dec 2022: revenue $98M, net income $-231M$98MFY22Fiscal year ending Dec 2023: revenue $156M, net income $-257M$156MFY23Fiscal year ending Dec 2024: revenue $103M, net income $-232M$103MFY24Fiscal year ending Dec 2025: revenue $114M, net income $-3M$114MFY25
Fiscal year endingRevenueGrowthOperating incomeNet incomeNet margin
Dec 2025$114M+10.4%$-20M$-3M-2.7%
Dec 2024$103M-33.8%$-120M$-232M-224.5%
Dec 2023$156M+59.5%$-160M$-257M-164.7%
Dec 2022$98M—$-179M$-231M-235.3%
Dec 2021——$26M$-29M—
Dec 2020$88M-41.2%$-117M$-183M-207.4%
Dec 2019$150M+308.0%$-70M$-112M-74.3%
Dec 2018$37M—$-124M$-162M-440.6%

Cash flow, debt and per share

Fiscal year endingOperating cash flowCapital spendingFree cash flowEPS (diluted)Dividend / share
Dec 2025$-77M$0M$-77M$0.00—
Dec 2024$-158M$1M$-159M$-10.59—
Dec 2023$-224M$10M$-234M$-13.75—
Dec 2022$-175M$53M$-228M$-15.64—
Dec 2021$10M$34M$-24M$-0.11—
Dec 2020$-139M$3M$-143M$-1.05—
Dec 2019$-19M$5M$-23M$-0.80—
Dec 2018$-131M$4M$-135M$-1.44—

Quarterly results

USD · three months to · source: SEC filings
Revenue, trailing 12 months
$134M
Net income, trailing 12 months
$31M
RevenueNet income
Three months to Dec 2024 (from the annual report): revenue $27M, net income $-47M$27MDec ’24Three months to Mar 2025: revenue $24M, net income $-26M$24MMar ’25Three months to Jun 2025: revenue $26M, net income $-30M$26MJun ’25Three months to Sep 2025: revenue $30M, net income $64M$30MSep ’25Three months to Dec 2025 (from the annual report): revenue $34M, net income $-11M$34MDec ’25Three months to Mar 2026: revenue $34M, net income $39M$34MMar ’26Three months to Jun 2026: revenue $35M, net income $-1M$35MJun ’26Three months to Sep 2026: revenue $31M, net income $3M$31MSep ’26

Latest quarter to Sep 2026: revenue $31M (+4.1% on a year earlier), net income $3M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Sep 2026.

SEC filings

Official filings of Agenus Inc. with the US Securities and Exchange Commission.

Annual results

Revenue
$114 M
Operating income
$-20 M
Net income
$-3 M

For year ending December-2025 · source: SEC filing

Balance sheet

Total assets
$227 M
Total liabilities
$505 M
Total equity
$-271 M

As of December-2025

Top 100 institutional investors in Agenus Inc.#

As of Sep 30, 2026
125 institutions held 26.3 M shares (about 58.1% of the shares outstanding) on Sep 30, 2026. The ten largest hold 43.3%. Source: SEC Form 13F filings, filed through Nov 18, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in Agenus Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Ra Capital Management, L.P.4,122,000New9.11%$41 MNov 16, 2026
2BlackRock, Inc.2,937,807+372,923 (+14.54%)6.49%$29 MNov 13, 2026
3Eventide Asset Management, LLC2,446,789New5.41%$24 MNov 13, 2026
4Siren, L.L.C.2,419,263+1,355,013 (+127.32%)5.35%$24 MNov 12, 2026
5Commodore Capital LP1,985,387New4.39%$20 MNov 16, 2026
6Vanguard Capital Management LLC1,687,245+11,149 (+0.67%)3.73%$17 MNov 13, 2026
7Vanguard Portfolio Management LLC1,367,782-59,805 (-4.19%)3.02%$14 MNov 13, 2026
8Geode Capital Management, LLC1,011,641-23,399 (-2.26%)2.24%$10 MNov 6, 2026
9Goldman Sachs Group Inc825,001+376,618 (+83.99%)1.82%$8 MNov 16, 2026
10Marshall Wace, LLP786,350+346,729 (+78.87%)1.74%$8 MNov 13, 2026
11State Street Corp756,378+343,995 (+83.42%)1.67%$8 MNov 12, 2026
12TCG Crossover Management, LLC603,892New1.33%$6 MNov 16, 2026
13Globeflex Capital L P418,5810 (0.00%)0.93%$4 MNov 16, 2026
14Morgan Stanley381,104+119,036 (+45.42%)0.84%$4 MNov 13, 2026
15Northern Trust Corp297,170-16,882 (-5.38%)0.66%$3 MNov 16, 2026
16Renaissance Technologies LLC281,326+52,980 (+23.20%)0.62%$3 MNov 12, 2026
17Vanguard Fiduciary Trust Co242,638-28,976 (-10.67%)0.54%$2 MNov 13, 2026
18D. E. Shaw & Co., Inc.239,718New0.53%$2 MNov 16, 2026
19Susquehanna International Group, LLP235,190+193,174 (+459.76%)0.52%$2 MNov 16, 2026
20UBS Group AG207,677+188,401 (+977.39%)0.46%$2 MNov 10, 2026
21XTX Topco Ltd179,011+147,361 (+465.60%)0.40%$2 MNov 16, 2026
22Connor, Clark & Lunn Investment Management Ltd.158,447-151,588 (-48.89%)0.35%$2 MNov 10, 2026
23Two Sigma Investments, LP157,185+58,500 (+59.28%)0.35%$2 MNov 16, 2026
24First Trust Advisors LP152,562New0.34%$2 MNov 12, 2026
25AQR Capital Management LLC151,615New0.34%$2 MNov 16, 2026
Show all 100: investors 26 to 100
Institutional investors 26 to 100 in Agenus Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Point72 Asset Management, L.P.150,831New0.33%$1 MNov 16, 2026
27Wellington Management Group LLP143,777New0.32%$1 MNov 16, 2026
28Susquehanna Portfolio Strategies, LLC143,408-15,329 (-9.66%)0.32%$1 MNov 16, 2026
29Prudential Financial Inc128,052+108,642 (+559.72%)0.28%$1 MNov 16, 2026
30Bank of New York Mellon Corp124,155+22,382 (+21.99%)0.27%$1 MNov 5, 2026
31Citadel Advisors LLC124,141New0.27%$1 MNov 16, 2026
32Charles Schwab Investment Management Inc111,339+11,947 (+12.02%)0.25%$1 MNov 16, 2026
33Panagora Asset Management Inc99,246-80,343 (-44.74%)0.22%$1 MNov 12, 2026
34Nuveen, LLC79,850New0.18%$1 MNov 10, 2026
35Jane Street Group, LLC64,387New0.14%$1 MNov 12, 2026
36Man Group plc63,254-277,171 (-81.42%)0.14%$1 MNov 16, 2026
37HighTower Advisors, LLC57,791New0.13%$1 MNov 10, 2026
38Price T Rowe Associates Inc /MD/57,6560 (0.00%)0.13%$1 MNov 16, 2026
39Rhumbline Advisers50,631+21,143 (+71.70%)0.11%$1 MNov 10, 2026
40Strs Ohio46,500-30,400 (-39.53%)0.10%$0 MOct 30, 2026
41Jpmorgan Chase & Co45,411+28,294 (+165.30%)0.10%$0 MNov 12, 2026
42Captrust Financial Advisors38,870+9,898 (+34.16%)0.09%$0 MNov 12, 2026
43Bank Of America Corp /de/35,597-16,415 (-31.56%)0.08%$0 MNov 16, 2026
44Invesco Ltd.35,558-15,380 (-30.19%)0.08%$0 MNov 12, 2026
45Creative Planning34,652New0.08%$0 MNov 2, 2026
46Deutsche Bank AG\33,816-5,088 (-13.08%)0.07%$0 MNov 6, 2026
47Vanguard Global Advisers, LLC33,746+17,840 (+112.16%)0.07%$0 MNov 13, 2026
48Vanguard Personalized Indexing Management, LLC29,618+10,419 (+54.27%)0.07%$0 MNov 16, 2026
49Claro Advisors Inc.26,196-7,154 (-21.45%)0.06%$0 MNov 2, 2026
50LPL Financial LLC24,177+11 (+0.05%)0.05%$0 MNov 6, 2026
51Osaic Holdings, Inc.23,450-10 (-0.04%)0.05%$0 MNov 12, 2026
52State of Wyoming22,701New0.05%$0 MOct 28, 2026
53Squarepoint Ops LLC22,425New0.05%$0 MNov 9, 2026
54MetLife Investment Management, LLC22,271New0.05%$0 MNov 16, 2026
55Group One Trading LLC20,456+19,895 (+3546.35%)0.05%$0 MNov 10, 2026
56MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.18,304-43 (-0.23%)0.04%$0 MNov 16, 2026
57Wells Fargo & Company/mn18,243-24,974 (-57.79%)0.04%$0 MNov 16, 2026
58Blueshift Asset Management, LLC17,791New0.04%$0 MNov 13, 2026
59FMR LLC16,438+3,156 (+23.76%)0.04%$0 MNov 10, 2026
60Millennium Management LLC16,351New0.04%$0 MNov 16, 2026
61Key Client Fiduciary Advisors, LLC15,536-8,589 (-35.60%)0.03%$0 MOct 19, 2026
62Bank Of Montreal /can/15,5150 (0.00%)0.03%$0 MNov 9, 2026
63Barclays PLC14,832+5,635 (+61.27%)0.03%$0 MNov 6, 2026
64Brown Advisory Inc14,000New0.03%$0 MNov 16, 2026
65HSBC Holdings PLC13,525+2,349 (+21.02%)0.03%$0 MNov 16, 2026
66Lazard Asset Management LLC12,801New0.03%$0 MNov 16, 2026
67Post Resch Tallon Group Inc.12,7500 (0.00%)0.03%$0 MOct 9, 2026
68Alliancebernstein L.P.12,3800 (0.00%)0.03%$0 MNov 16, 2026
69Greenwich Wealth Management LLC12,000New0.03%$0 MNov 16, 2026
70Abel Hall, LLC11,987+227 (+1.93%)0.03%$0 MOct 19, 2026
71Values First Advisors, Inc.10,793-191 (-1.74%)0.02%$0 MOct 23, 2026
72Baird Financial Group, Inc.10,620New0.02%$0 MNov 13, 2026
73Manufacturers Life Insurance Company, The10,297New0.02%$0 MNov 13, 2026
74Everhart Financial Group, Inc.10,100New0.02%$0 MOct 8, 2026
75Police & Firemen's Retirement System of New Jersey10,042-5,300 (-34.55%)0.02%$0 MNov 9, 2026
76BNP Paribas Financial Markets8,282-13,614 (-62.18%)0.02%$0 MNov 12, 2026
77Russell Investments Group, Ltd.5,732+2,118 (+58.61%)0.01%$0 MNov 6, 2026
78Legal & General Group Plc3,8640 (0.00%)0.01%$0 MNov 16, 2026
79Ameritas Investment Partners, Inc.3,6160 (0.00%)0.01%$0 MNov 13, 2026
80UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC3,396+3,111 (+1091.58%)0.01%$0 MNov 16, 2026
81Pinnacle Wealth Planning Services, Inc.3,3730 (0.00%)0.01%$0 MOct 27, 2026
82Federated Hermes, Inc.2,887-493 (-14.59%)0.01%$0 MNov 12, 2026
83Caitong International Asset Management Co., Ltd2,215+582 (+35.64%)0.00%$0 MOct 29, 2026
84New York State Common Retirement Fund2,100-16,800 (-88.89%)0.00%$0 MNov 17, 2026
85Arax Advisory Partners2,086+2,081 (+41620.00%)0.00%$0 MNov 12, 2026
86Royal Bank Of Canada2,075+163 (+8.53%)0.00%$0 MNov 16, 2026
87Citigroup Inc1,882-25,820 (-93.21%)0.00%$0 MNov 4, 2026
88Atlantic Union Bankshares Corp1,7500 (0.00%)0.00%$0 MNov 12, 2026
89Tower Research Capital LLC (TRC)1,378-933 (-40.37%)0.00%$0 MNov 16, 2026
90Chilton Capital Management LLC1,0580 (0.00%)0.00%$0 MOct 28, 2026
91Optiver Holding B.V.1,014+440 (+76.66%)0.00%$0 MNov 16, 2026
92Covestor Ltd9150 (0.00%)0.00%$0 MOct 30, 2026
93Nisa Investment Advisors, LLC8470 (0.00%)0.00%$0 MOct 20, 2026
94Sterling Capital Management LLC830+125 (+17.73%)0.00%$0 MOct 22, 2026
95GAMMA Investing LLC787New0.00%$0 MOct 8, 2026
96SBI Securities Co., Ltd.695+683 (+5691.67%)0.00%$0 MOct 22, 2026
97Physician Wealth Advisors, Inc.682+61 (+9.82%)0.00%$0 MOct 20, 2026
98Huntington National Bank6640 (0.00%)0.00%$0 MNov 10, 2026
99Northwestern Mutual Wealth Management Co6330 (0.00%)0.00%$0 MNov 13, 2026
100Game Plan Financial Advisors, LLC5850 (0.00%)0.00%$0 MNov 10, 2026

All 125 institutional investors, with who bought and sold →

Mutual funds holding Agenus Inc.#

62 funds hold shares worth $22 M (about 12.9% of the company). Since their previous reports 49 added shares and 3 sold, buying $11 M net.
Mutual funds holding Agenus Inc.
FundSharesValueOf the companyOf the fundChange in sharesReport
🇺🇸 Vanguard Total Stock Market Index FundThe Vanguard Group, Inc.1.16 M$4 M2.6%<0.01%+13%Jun 30, 2026
🇺🇸 Fidelity Small Cap Index FundFidelity Management & Research Company LLC435,952$3 M0.96%<0.01%newJul 31, 2026
🇺🇸 iShares Russell 2000 ETFBlackRock Fund Advisors903,711$3 M2.0%<0.01%newJun 30, 2026
🇺🇸 Vanguard Explorer FundThe Vanguard Group, Inc.290,646$2 M0.64%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Strategic Equity FundThe Vanguard Group, Inc.511,809$2 M1.1%0.01%no changeJun 30, 2026
🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc.485,158$1 M1.1%<0.01%+25%Jun 30, 2026
🇺🇸 iShares Russell 2000 Value ETFBlackRock Fund Advisors258,455$1 M0.57%<0.01%newJun 30, 2026
🇺🇸 iShares Russell 2000 Growth ETFBlackRock Fund Advisors256,842$1 M0.57%<0.01%newJun 30, 2026
🇺🇸 Schwab Small-Cap Index FundCharles Schwab Investment Management, Inc.96,310$1 M0.21%<0.01%newJul 31, 2026
🇺🇸 Vanguard Strategic Small-Cap Equity FundThe Vanguard Group, Inc.205,345$1 M0.45%0.02%no changeJun 30, 2026
🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC163,921$1 M0.36%<0.01%+25%May 31, 2026
🇺🇸 iShares Micro-Cap ETFBlackRock Fund Advisors133,984$0 M0.30%0.03%+65%Jun 30, 2026
🇺🇸 Small Company Growth PortfolioThe Vanguard Group, Inc.114,747$0 M0.25%0.02%−25%Jun 30, 2026
🇺🇸 Siit Small Cap II FundSEI INVESTMENTS MANAGEMENT CORPORATION84,700$0 M0.19%0.12%newMay 31, 2026
🇺🇸 PGIM Quant Solutions Small-Cap Value FundPGIM INVESTMENTS LLC39,500$0 M0.09%0.07%newJul 31, 2026
🇺🇸 Master Small Cap Index SeriesBlackRock Advisors, LLC74,480$0 M0.16%<0.01%newJun 30, 2026
🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC60,552$0 M0.13%<0.01%no changeMay 31, 2026
🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC50,643$0 M0.11%<0.01%+6.1%May 31, 2026
🇺🇸 Fidelity ZERO Total Market Index FundFidelity Management & Research Company LLC23,081$0 M0.05%<0.01%+33%Jul 31, 2026
🇺🇸 Fidelity Small Cap Value Index FundFidelity Management & Research Company LLC47,606$0 M0.11%<0.01%newJun 30, 2026
🇺🇸 Global X Russell 2000 ETFGlobal X Management Company LLC19,052$0 M0.04%<0.01%newJul 31, 2026
🇺🇸 Acuitas US Microcap FundAcuitas Investments, LLC45,503$0 M0.10%0.12%—Jun 30, 2026
🇺🇸 EQ/2000 Managed Volatility PortfolioEquitable Investment Management Group, LLC40,407$0 M0.09%<0.01%newJun 30, 2026
🇺🇸 Goldman Sachs Absolute Return Tracker FundGoldman Sachs Asset Management, L.P.39,218$0 M0.09%<0.01%+94%Jun 30, 2026
🇺🇸 Fidelity ZERO Extended Market Index FundFidelity Management & Research Company LLC15,259$0 M0.03%<0.01%+29%Jul 31, 2026
🇺🇸 Schwab Total Stock Market Index FundCharles Schwab Investment Management, Inc.15,000$0 M0.03%<0.01%no changeJul 31, 2026
🇺🇸 Vanguard Market Neutral FundThe Vanguard Group, Inc.33,574$0 M0.07%0.02%no changeJun 30, 2026
🇺🇸 LVIP State Street Small-Cap Index FundLincoln Financial Investments Corporation31,100$0 M0.07%<0.01%newJun 30, 2026
🇺🇸 Fidelity Nasdaq Composite Index FundFidelity Management & Research Company LLC22,604$0 M0.05%<0.01%no changeMay 31, 2026
🇺🇸 T. Rowe Price Extended Equity Market Index FundT. Rowe Price Associates, Inc.24,500$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Small Cap Index FundNorthern Trust Investments, Inc.21,138$0 M0.05%<0.01%newJun 30, 2026
🇺🇸 Vanguard Balanced Index FundThe Vanguard Group, Inc.20,381$0 M0.05%<0.01%no changeJun 30, 2026
🇺🇸 Fidelity Flex Small Cap Index FundFidelity Management & Research Company LLC6,714$0 M0.01%0.01%+28%Jul 31, 2026
🇺🇸 SA Small Cap Index PortfolioSunAmerica Asset Management, LLC4,666$0 M0.01%<0.01%newJul 31, 2026
🇺🇸 Small-Cap Index PortfolioPacific Life Fund Advisors LLC11,017$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Vanguard Institutional Total Stock Market Index FundThe Vanguard Group, Inc.10,885$0 M0.02%<0.01%no changeJun 30, 2026
🇺🇸 Victory Extended Market Index FundVictory Capital Management Inc.4,329$0 M<0.01%<0.01%+25%Jul 31, 2026
🇺🇸 1290 VT Micro Cap PortfolioEquitable Investment Management Group, LLC9,037$0 M0.02%0.01%+56%Jun 30, 2026
🇺🇸 ATM Small Cap Managed Volatility PortfolioEquitable Investment Management Group, LLC8,388$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 Nationwide Small Cap Index FundNATIONWIDE FUND ADVISORS3,415$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 NVIT Small Cap Index FundNATIONWIDE FUND ADVISORS8,258$0 M0.02%<0.01%newJun 30, 2026
🇺🇸 SmallCap Value Fund IIPrincipal Global Investors, LLC2,763$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 DWS Small Cap Index VIPDWS Investment Management Americas, Inc.6,177$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/AB Small Cap Growth PortfolioEquitable Investment Management Group, LLC6,190$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Small Company Index PortfolioEquitable Investment Management Group, LLC6,190$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 T. Rowe Price Small-Cap Index FundT. Rowe Price Associates, Inc.6,078$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 Fidelity Small Cap Growth Index FundFidelity Management & Research Company LLC5,605$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 BlackRock Small Cap Index V.I. FundBlackRock Advisors, LLC5,194$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 1290 VT Small Cap Value PortfolioEquitable Investment Management Group, LLC4,868$0 M0.01%<0.01%newJun 30, 2026
🇺🇸 CVT Russell 2000 Small Cap Index PortfolioCalvert Research and Management3,616$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Venerable Small Cap Index FundVenerable Investment Advisers, LLC3,181$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Extended Market Index PortfolioFidelity Management & Research Company LLC2,466$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 PD Small-Cap Value Index PortfolioPacific Life Fund Advisors LLC2,091$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 EQ/Franklin Small Cap Value Managed Volatility PortfolioEquitable Investment Management Group, LLC1,778$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Small-Cap Equity PortfolioPacific Life Fund Advisors LLC1,209$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 SmallCap Growth Fund IPrincipal Global Investors, LLC451$0 M<0.01%<0.01%newJul 31, 2026
🇺🇸 State Street Total Return V.I.S. FundSSGA Funds Management, Inc.1,006$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 VIP Total Market Index PortfolioFidelity Management & Research Company LLC834$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Total Stock Market Index TrustJohn Hancock Variable Trust Advisers LLC710$0 M<0.01%<0.01%+19%Jun 30, 2026
🇺🇸 State Street Balanced Index FundSSGA Funds Management, Inc.551$0 M<0.01%<0.01%no changeJun 30, 2026
🇺🇸 State Street Small/mid Cap Equity Index PortfolioSSGA Funds Management, Inc.500$0 M<0.01%<0.01%newJun 30, 2026
🇺🇸 Knights of Columbus U.S. ALL CAP INDEX FUNDKnights of Columbus Asset Advisors LLC204$0 M<0.01%<0.01%+13%Jul 31, 2026

Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jul 31, 2026. The 62 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.

Insider trading at Agenus Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$0
0 purchases, 0 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$0
open market only
Insiders on file
21
since
$325 K$0Nov 2023: bought $19 K (1 trades), sold $0 (0 trades)Nov 23Feb 2024: bought $325 K (1 trades), sold $0 (0 trades)Feb
Bought (open market)Sold (open market)Hover a month for the totals
Agenus Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed Thomas L. HarrisonDirectorGrant or award+4,443$6.893$31 K51,988Form 4
filed Garo H. ArmenSee Remarks, DirectorGrant or award+4,852$3.350$16 K371,108Form 4
filed Thomas L. HarrisonDirectorGrant or award+8,547$3.580$31 K47,545Form 4
filed Garo H. ArmenSee Remarks, DirectorGrant or award+5,364$3.030$16 K366,256Form 4
filed Garo H. ArmenSee Remarks, DirectorGrant or award+4,925$3.300$16 K360,892Form 4
filed Garo H. ArmenSee Remarks, DirectorGrant or award+4,644$3.500$16 K355,967Form 4
filed Garo H. ArmenSee Remarks, DirectorGrant or award+4,540$3.580$16 K351,323Form 4
filed Garo H. ArmenSee Remarks, DirectorGrant or award+4,233$3.840$16 K346,783Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: Agenus Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
7.6 M
21.5% of shares · 10.68 days to cover
Buybacks, Q4 2010
$0M
Q4 2011
Shares sold short, last 24 reportsAll stocks →
Agenus Inc. share buybacks by quarter
Buybacks, quarterFiscalSpent
Q4 2010Q4 2011$0M
Q3 2010Q3 2011$0M

Trading halts

  • 2025-12-19 15:43 UTC, code LUDP, resumed 15:48 UTC
  • 2025-12-19 15:33 UTC, code LUDP, resumed 15:43 UTC
  • 2025-06-03 10:55 UTC, code T3, resumed 11:30 UTC

Fails to deliver

  • : 995 shares at $6.40
  • : 23 shares at $8.70
  • : 108 shares at $8.33
  • : 69 shares at $7.85
  • : 22 shares at $7.22

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

Agenus Inc. scorecard#

Passes 8 of the 18 checks that could be worked out: strongest in valuation (3 of 5), weakest in financial health (0 of 3). Fiscal year 2025; market cap of Oct 22, 2026.

  • Valuation3 of 5
    • ✓P/E below its peers' median9.4×P/E 9.4× against Biotechnology's median of 17.5×.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • ✓Price to sales below its peers' median2.2×Price to sales 2.2× against Biotechnology's median of 8.7×.
    • ✗Free cash flow yield above 5%-26.7%Free cash flow is -26.7% of the market value.
    • ✓Earnings yield above the 10-year Treasury yield10.6%Earnings yield 10.6% against the 10-year Treasury's 5.15% on 2026-11-13.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growth3 of 5
    • ✓Revenue grew in the newest year10.4%Revenue up 10.4% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years5.2%5.2% a year over the three years to fiscal 2025.
    • ✗Faster growth over three years than its peers' median5.2%5.2% a year against Biotechnology's median of 12.9% (181 companies).
    • ✗Earnings per share grew in the newest year0.00 vs -10.59Diluted EPS 0.00 in fiscal 2025 against -10.59 the year before (report's currency).
    • ✓Net income higher than five years earlier-$3 M-$3 M in fiscal 2025 against -$183 M in 2020.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability2 of 4
    • ✗Profitable in the newest year-$3 MNet income -$3 M in fiscal 2025.
    • ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
    • ✓Operating margin above its peers' median-17.7%-17.7% against Biotechnology's median of -60.5% (243 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier-17.7%-17.7% in fiscal 2025 against -183.1% in 2022.
  • Financial health0 of 3
    • ✗Short-term assets cover short-term liabilities0.4×Current ratio 0.41 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
    • ✗Altman Z-score outside the distress zone-13.93Z-score -13.93 (distress zone) for fiscal 2025.
  • Shareholder returns0 of 1
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✗Share count up no more than 2% in a year38.5%Diluted shares up 38.5% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Financial analysis, 2025#

Worked out from Agenus Inc.'s statements, beside the median of Biotechnology.

Agenus Inc.: main financial ratios in 2025
Ratio2025Median of peers
Operating margin-17.7%-60.5%
Net margin-2.7%-68.9%
Revenue growth, 3 years a year5.2%12.9%
Revenue growth10.4%15.8%
Free cash flow margin-67.6%-61.5%

4of 9on the Piotroski tests of financial strength

  • Net loss of $3 million, the 17th loss-making year in a row.
  • Free cash flow was negative: -$77 million.
  • The share count rose 38.5% in the year.
  • Shareholders' equity is negative: -$271 million.

Agenus Inc.: financial statements#

Income statement, balance sheet and cash-flow statement as reported, newest period first.

Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).

Agenus Inc.: statements by fiscal year
PeriodTrendFY 2025to Dec 31, 2025FY 2024to Dec 31, 2024FY 2023to Dec 31, 2023FY 2022to Dec 31, 2022FY 2021to Dec 31, 2021FY 2020to Dec 31, 2020FY 2019to Dec 31, 2019FY 2018to Dec 31, 2018FY 2017to Dec 31, 2017FY 2016to Dec 31, 2016
Income statement
Revenue114103156982968815037r4323
Cost of revenue1.00.53.1113.52.3————
Research and development79156235187179143168125r116r95
General and administrative5472798176594637r34r33
Operating income−20−120−160−17926−117−70−124r−104r−107
Interest and finance income0.32.85.92.3——————
Interest expense and finance costs5612010464————3119
Provision for credit losses000———————
Share of profit of associates−2600———————
Other non-operating income (expense)−2.25.80.0135.1−1.90.0−2.2r2.0r−2.2
Income before tax−3.1−232−257—————−121−127
Income tax0000000000
Net income including minority interests−3.1−232−257r−231r−29r−183r−112−162r−121r−127
Minority interests' share of net income−3.2−5.1−12−11−4.8−2.0−3.9−2.4r——
Net income attributable to shareholders————————−121−127
Earnings per share, basic0.00-10.59-13.75r-15.64r-0.11-1.05-0.80-1.44-1.23-1.46
Earnings per share, diluted0.00-10.59-13.75r-15.64r-0.11-1.05-0.80-1.44-1.23-1.46
Shares, weighted average (basic)302118r14r0.20.2————
Shares, weighted average (diluted)302118r14r0.20.20.10.1r0.1r87
Balance sheet
Cash and cash equivalents3.040761792921006253r6071
Short-term investments0——1515————5.0
Receivables1.80.4262.71.51.2160.9r1.111
Inventory——————00.1r0.10.1
Other current assets1.12.42.43.23.22.01.01.5r1.10.8
Current assets133461122133321148775r7491
Property, plant and equipment1512013313360272625r2626
Right-of-use (leased) assets7.727303131337.4———
Goodwill2424252525252323r2322
Other intangible assets3.03.44.46.28.5111112r1416
Investments in associates240————————
Total assets227226314414466215155136r138157
Accounts payable8361614130171414r8.15.4
Debt due within a year452.70.10.60.70.80.60.1r210.1
Current liabilities32322125618915713012268r5641
Long-term debt030131313191313r142131
Lease liabilities (non-current)1055636342348.0———
Retained earnings−2,183−2,183−1,956−1,710−1,490−1,466−1,285−1,177r−1,026−905
Shareholders' equity−271−326−160−6134−204−225−172r−76−39
Minority interests−6.820126.413−7.8−6.0−2.1r——
Total equity−278−306−148−5548−211−231−175r−76r−39r
Total liabilities and equity227226314414466215155136r138157
Shares outstanding352420———————
Cash-flow statement
Depreciation and amortization10.013146.96.87.26.76.3r6.0r4.9
Share-based compensation1417231820109.97.6r12r13
Cash from operating activities−77−158−224−17510−139−19−131r−94r−80
Capital expenditure−0.0−0.6−10.0−53−34−3.5−4.7−3.6r−3.1r−13
Cash from investing activities1.20.03.4−34−43−4.4−4.7−3.6r2.1r18
Debt issued—————6.2——15—
Debt repaid−2.5———−0.5−1.5—−162r——
Cash from financing activities371231209622518431128r81r−2.5
Change in cash−39−36−102−113192418.8−7.1r−11r−65
Report10-K10-K10-K10-K10-K10-K10-K10-K10-K10-K

r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies

Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.

Source: SEC EDGAR filings (XBRL) · as of Sep 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative

What Agenus Inc. sells: revenue by product line, fiscal 2025#

As the company reports it, in US dollars, with each line's share of total revenue and the change on fiscal 2024. Lines can overlap (a total and its parts), so they are not added up.

Products and services

  • Non-Cash Revenue Related to the Sale of Future Royalties$109 M95%
  • Non-cash royalties$109 M95%
  • Pre-Commercial Product Revenue$4 M3.7%
  • Other services$1 M0.9%
  • Service Revenue$1 M0.9%
  • Research and Development$0 M0.3%
  • Clinical product revenue$0 M0.3%

Countries and regions

Source: SEC annual report (XBRL data) · as of Dec 31, 2025

Executive pay at Agenus Inc.#

From the pay-versus-performance table of the company's proxy statement. “Actually paid” marks share awards to their current value.

CEO total pay, fiscal 2025
$1.4 M
Dr. Armen
Other top executives, average
$617 K
the CEO earned 2.2× this
$100 invested is now
$7
Agenus Inc.: executive pay by fiscal year
Fiscal yearCEO total payActually paidOther executives, average$100 invested
2025Dr. Armen$1.4 M$3.6 M$617 K$7
2024Dr. Armen$4.1 M$2.9 M$927 K$3
2023Dr. Armen$5.9 M−$1.5 M$1.1 M$20

Source: SEC proxy statement (Form DEF 14A) · as of Dec 31, 2025

Events at Agenus Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Restructuring 1 · Acquisition or sale completed 1 · Directors and officers 5 · Material agreement 8 · Agreement ended 1 · New debt 4 · Unregistered share sale 5 · Shareholder rights changed 1 · Shareholder vote 2 · Results announced 9

Agenus Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Directors and officers8-K
Directors and officers8-K
Results announced8-K
Material agreementUnregistered share sale8-K
Material agreement8-K
Shareholder vote8-K
Directors and officers8-K
Results announced8-K
Results announced8-K
Acquisition or sale completedUnregistered share sale8-K
Directors and officers8-K
Material agreementShareholder rights changed8-K
Results announced8-K
Material agreementNew debt8-K
Results announced8-K
Shareholder vote8-K
Material agreement8-K
Results announced8-K
Results announced8-K
Material agreementNew debtUnregistered share sale8-K
Agreement ended8-K
Restructuring8-K
Material agreementNew debtUnregistered share sale8-K
Results announced8-K
Directors and officers8-K/A

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 5, 2026

Acquisitions and funding#

Private share sales · funding history

Private share sales of Agenus Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jan 2019$30 MPrivate placement after listing$10 to $50 million1equitySEC
Oct 2018$40 MPrivate placement after listing$10 to $50 million2equitySEC
Feb 2017$60 MPrivate placement after listing$50 to $250 million1equitySEC
Dec 2015$7 MPrivate placement after listing$2 to $10 million17equitySEC
Sep 2015$2 MPrivate placement after listing$2 to $10 million2equitySEC
Feb 2015$21 MPrivate placement after listing$10 to $50 million8debt, optionsSEC
Feb 2015$35 MPrivate placement after listing$10 to $50 million1equitySEC
Apr 2013$5 MPrivate placement after listing$2 to $10 million3debt, optionsSEC
Aug 2009$10 MPrivate placement after listing$10 to $50 million4equity, optionsSEC
Aug 2009$10 MPrivate placement after listing$10 to $50 million1equity, optionsSEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

Lobbying by Agenus Inc.#

$30 K spent on lobbying the US Congress and federal agencies in 2024, most often on medical/disease research/clinical labs and health issues.

Lobbying, 2024
$30 K
#1,298 among companies on value.today
Own lobbyists
No
only outside firms
Firms hired
1
in 2024
2026 so far
—
  • Medical/Disease Research/Clinical Labs1 report
  • Health Issues1 report

Lobbying firms hired in 2024

TIDES GROUP, LLC $30 K

Agenus Inc.: lobbying spending by year
YearSpendingOwn lobbyistsReports
2024$30 K—1
2023$105 K—3
2019$0—2
2018$20 K—4

Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Agenus Inc.”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero

H-1B hiring at Agenus Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $250 K a year.

Certified, FY2026
1
#1,819 among companies on value.today
Worker positions
1
Median wage offered
$250 K
a year, full-time
Applications filed
1
Agenus Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Senior Director, Statistical ProgrammingBiostatisticians1$250 K

Where: Piscataway, NJ 1

Agenus Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$250 K1
FY202544$140 K4
FY202433$191 K3
FY202344$96 K4
FY202277$88 K7
FY202188$100 K8
FY202055$102 K5

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Agenus Inc.

Layoffs at Agenus Inc.#

From US state WARN notices and SEC 8-K restructuring filings, newest first.

People, last 12 months
0
0 notices and filings
People, all years
131
2005–2024
Latest
—
2024-12-05
Agenus Inc.: people laid off by year and month
YearJanFebMarAprMayJunJulAugSepOctNovDecTotal
2024············—
2023············—
2009·19··········19
2006····42·······42
2005···········7070
Agenus Inc.: latest layoffs
AnnouncedPeopleKindWhereSource
Not statedRestructuring planSEC 8-KCompany-wide planFiling
25% of workforceRestructuring planSEC 8-K“(excluding its independently operating subsidiaries) is reducing its workforce by approximately 25%, which the company expects to result in savings of approximately $2.8 million by…”Filing
19 people (20% of workforce)Restructuring planSEC 8-K“(the “Company”) initiated a plan of restructuring that resulted in a reduction of its workforce by approximately 20%, or 19 positions.”Filing
42 peopleRestructuring planSEC 8-K“During the quarter ending June 30, 2006, the Company will eliminate 42 positions and has estimated its costs related to this reduction to be approximately $535,000.”Filing
70 peopleRestructuring planSEC 8-K“As part of these strategies, the Company has terminated approximately 70 employees and has estimated its costs related to these terminations and other related activities to be appr…”Filing

Source: State WARN notices and SEC 8-K item 2.05

How Agenus Inc. compares in Biotechnology

  • Market cap$290 M · higher than 50% of 726
  • Revenue$114 M · higher than 70% of 647
  • Net margin23.0% · higher than 88% of 408
  • Revenue growth10.4% · higher than 54% of 438
  • P/E ratio9.4× · lower than 75% of 100
  • Price / sales2.2× · lower than 84% of 339
  • FCF yield-26.7% · higher than 37% of 449

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
Agenus Inc.🇺🇸$290 M9.4×23.0%+10.4%
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 22, 2026
Annual results:
For year ending December-2025
Balance sheet:
As of December-2025
Employees:
As on 2021
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research, Wikidata, Wikipedia, Wikimedia Commons, GLEIF register; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at Agenus Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show Agenus Inc.'s ranking or a chart on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about Agenus Inc.? Suggest a correction